"What is claimed is: 1. An isolated monoclonal anti60dy, whekein, when boond to PCSK9, said monoclonal antibody binds to at least one residue within the sequence 8et forth by residues 123 - 132 of SEQ ID NO: 1, and whekein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PC8K9 inhibition of cel1ulak LDL uptare.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the 8eqoence 8et forth 6y residues 123 - 132 0f SEQ ID NO: I, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain uf LDLR protein antagonizes PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated m0noc1unal antibody, wherein, when bound to PCSK9, said monoclonal anti6udy binds tu at least one residue within the sequence set forth by residues 123 - I32 of SEQ ID NO: 7, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when buund to PCSK9, said monoclonal antibody binds to at least une residue within the sequence set forth by residoe8 123 - 132 of SEQ ID N0: l, and wherein 8aid monoclonal antibody reduces binding between PGSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cel1olar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when buund to PCSK9, said monoclonal antibody bind8 to at least 0ne residue within the sequence 8et forth by residues 123 - 132 of SEQ ID NO: 1, and wherein 8aid monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition 0f cellular LDL uptare.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound t0 PCSK9, said monoclonal antibody binds to at least one kesidoe within the sequence 8et forth by residues 1z3 - 132 0f SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated m0nuc1onal anti60dy, whekein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 0f SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain 0f LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptare.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds t0 at least one residue within the sequence set forth by residues 123 - 132 of SEQ I0 NO: 7, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LOLR pkutein anta9uni2es PCSK9 inhi6itiun of cellular LOL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whekein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the 8eqoence set forth by residues 123 - 132 of SEQ ID NO: l, and wherein 8aid mon0c10nal anti6udy keduce8 binding between PGSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isu1ated monoclonal antibody, wherein, when buund to PCSK9, said monoclonal antibody binds t0 at least one re8idoe within the 8eqoence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of L0LR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSKg, said monoclonal anti6udy binds to at least one residue within the sequence 8et forth 6y residoe8 123 - 132 0f SEQ ID NO: 1, and wherein said monoclonal antibody reduces 6indin9 6etween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: I. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody 6inds to at 1east une residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody keduce8 binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhi6iti0n of cellular LDL uptake.","123-132, 1"
"What is claimed is: l. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one ke8idue within the sequence set forth by residues 123 - 132 of SEQ ID N0: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa d0main of LDLR protein antaguni2e8 PCSK9 inhibition of cellular LDL uptare.","123-132, 1"
"What is claimed is: l. An i8o1ated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least 0ne residue within the 8eqoence set forth by residues 123 - 732 of SEQ ID NO: 1, and whekein said monoclonal antibody reduces binding 6etween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoc10na1 antibody, whekein, when buund to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain uf L0LR protein anta90ni2es PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when boond to PCSK9, 8aid monoclonal anti6udy binds to at least one residue within the sequence set forth by residues 123 - 132 of 8EQ ID NO: 1, and wherein said monoclonal anti6udy reduces binding between PCSK9 and an EGFa domain of LDLR protein anta9oni2e8 PCSK9 inhibition of cel1ulak LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whekein, when bound to PCSK9, said mun0clunal antibody binds to at 1east one residue within the sequence set forth by residues 123 - 132 uf SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding 6etween PCSK9 and an EGFa d0main of LDLR protein antagonizes PCSK9 inhibition 0f cellular L0L uptake.","123-132, 1"
"What is claimed is: 1. An is01ated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal anti6udy binds to at least one residue within the sequence set forth by kesidoes 123 - 132 of SEQ I0 NO: 1, and whekein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL optake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when boond tu PCSK9, said monoclonal antibody binds t0 at least une residue within the sequence set forth by residues I23 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding 6etween PGSK9 and an ECFa domain of LDLR protein antagonizes PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mun0c1onal antibody, whekein, when bound to PCSK9, said monuc1unal antibody binds to at lea8t one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said m0n0clona1 antibody reduces binding between PC8K9 and an ECFa domain 0f L0LR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal anti6udy, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 uf SEQ ID NO: 1, and whekein 8aid m0n0clona1 antibody reduces binding between PC8K9 and an EGFa domain of LDLR protein anta9unize8 PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What i8 c1aimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least une residue within the sequence set forth 6y residues l23 - 13z of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cel1olar LDL uptare.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bind8 to at least one residue within the sequence set forth by residues 123 - 13Z of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an BGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL optake.","123-132, 1"
"What is claimed is: 1. An isolated m0noc1ona1 anti6udy, wherein, when bound to PCSK9, said monoclonal antibody binds to at 1east one residue within the sequence set furth by residues 123 - 13z of SEQ ID NO: 1, and wherein said monoclonal antibody redoce8 binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhi6iti0n of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An is01ated monoclonal anti6udy, wherein, when bound to PCSK9, said monoclonal antibody binds tu at least one residue within the sequence set forth by residues 1z3 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of L0LR protein antagonizes PCSK9 inhi6itiun of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monuc10nal antibody, wherein, when bound to PCSK9, said mon0c10nal antibody binds to at lea8t 0ne residue within the sequence set forth by residues I23 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What i8 claimed is: 7. An isolated monoclonal antibody, wherein, when bound to PCSK9, said m0noc1ona1 antibody binds t0 at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID N0: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cello1ar L0L uptake.","123-132, 1"
"What is claimed is: 1. An isolated munocl0na1 antibody, wherein, when bound to PCSK9, said munucl0nal antibody binds t0 at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whekein said monoclonal antibody reduces binding between PCSK9 and an EGFa dumain of LDLR protein antagonizes PGSK9 inhibition of cellular L0L uptake.","123-132, 1"
"What i8 claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoc1una1 antibody bind8 to at least one residue within the sequence set forth by residues l23 - 132 of SEQ ID ND: 1, and wherein said monoclonal anti6udy reduces binding between PCSK9 and an EGFa domain 0f LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence 8et f0rth by kesidue8 123 - 132 uf SEQ ID ND: 1, and wherein said monoclonal antibody reduces binding 6etween PCSK9 and an EGFa domain 0f LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed i8: 1. An i80lated monoclonal antibody, wherein, when bound to PCSK9, 8aid monoclonal antibody binds to at least one residue within the sequence set forth by re8idoes 123 - 132 of SEQ ID ND: 1, and wherein said monoclonal anti60dy reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is c1aimed is: 1. An isolated monoclonal antibody, wherein, when bound t0 PCSK9, said monoclonal antibody binds to at least 0ne residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anti6udy reduces binding between PCSK9 and an EGFa d0main of LDLR protein anta9oni2e8 PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is c1aimed is: 4. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth 6y residoe8 123 - 132 uf SEQ ID N0: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of L0LR protein anta9uni2es PCSK9 inhi6itiun of cellular LDL uptake.","123-132, 1"
"What is c1aimed is: 1. An isolated monoclonal anti6udy, wherein, when bound to PCSK9, said mun0c1onal anti6udy binds to at least one residue within the sequence set furth by residues 123 - 132 of SEQ ID NO: l, and wherein said monoclonal antibody reduces 6indin9 6etween PCSK9 and an ECFa domain of LDLR protein antagonizes PCSK0 inhibition of cellular LDL uptake.","123-132, 1"
"What is c1aimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK0, said monoclonal antibody binds to at least une residue within the sequence set f0rth by kesidoes 123 - 132 of SEQ ID NO: 1, and whekein said mon0c1ona1 antibody reduces binding 6etween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least 0ne residue within the sequence set fokth by residues 123 - 132 uf 8EQ ID NO: l, and wherein 8aid monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PC8K9 inhibition of cellular LDL uptake.","123-132, 1"
"What i8 claimed i8: 1. An i80lated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bind8 to at least one residue within the sequence set furth by residues 123 - 13Z of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa d0main of LDLR protein antagonizes PCSK9 inhibition of cellular LDL optake.","123-132, 1"
"What is claimed is: 1. An isolated monuc1ona1 antibody, wherein, when bound tu PCSK9, said monoclonal antibody binds to at least one residue within the sequence 8et forth by residues 123 - 13Z of SEQ ID N0: 1, and wherein said monoclonal antibody reduces binding 6etween PGSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellolak LOL uptake.","123-132, 1"
"What is claimed is: 1. An isu1ated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at lea8t one residue within the sequence 8et forth by residues 123 - I32 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR pk0tein antagonizes PCSK9 inhibition of cellu1ak LDL uptake.","123-132, 1"
"What is c1aimed i8: 1. An isolated m0noc1ona1 antibody, whekein, when bound tu PCSK9, said monoclonal antibody binds tu at least one residue within the sequence set forth by residues 123 - 432 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PC8K9 and an ECFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 7. An isolated monoclonal anti6udy, wherein, when bound to PCSK9, said monoclonal antibody 6inds to at least one residue within the sequence set fokth by residues 123 - l32 of SEQ ID NO: 1, and wherein said monoclonal anti6udy reduces binding 6etween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of ce11ular LDL uptake.","123-132, 1"
"What is claimed is: 7. An isolated monoclonal antibody, whekein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the 8eqoence set forth by kesidoes 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anti6udy kedoces binding between PCSK9 and an EGFa domain of L0LR pkutein antagonizes PCSK9 inhibition of ce11ular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when buund to PCSK9, 8aid monoclonal antibody binds to at least one residue within the 8eqoence set forth by residues 123 - 132 uf SEQ ID NO: 1, and whekein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What i8 claimed is: 1. An isolated monoclonal antibody, whekein, when bound to PCSK0, said monoclonal antibody bind8 to at least une residue within the sequence set forth 6y residues 123 - 132 0f SEQ I0 NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an BGFa domain of LDLR protein antagonizes PCSK9 inhibition uf cellular LDL uptake.","123-132, 1"
"What i8 c1aimed is: 1. An isolated monoclonal antibody, wherein, when boond to PCSK9, said monoclonal anti60dy 6inds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anti6udy reduces binding between PCSK9 and an EGFa domain of LDLR protein anta90nize8 PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed i8: 1. An isolated monoclonal antibody, whekein, when bound to PGSK9, said monoclonal antibody binds to at least one residue within the sequence set forth 6y residues 123 - 132 of SEQ ID NO: 1, and wherein said m0nuc1onal anti60dy reduces binding between PGSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cel1ulak LDL uptare.","123-132, 1"
"What is claimed i8: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence 8et forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain uf LDLR pkutein antagonizes PGSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed i8: 1. An isolated monoclonal antibody, wherein, when boond to PCSK9, said monoclonal anti60dy binds to at least one residue within the sequence set fokth by residues 723 - 132 of SEQ ID NO: 1, and wherein said monoclonal anti6udy reduces binding between PCSK9 and an EGFa domain of L0LR protein antagonizes PCSK9 inhi6itiun of cellular L0L uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whekein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence 8et forth by residues 123 - 132 of SEQ ID ND: 1, and wherein said m0nocl0na1 antibody reduces binding 6etween PCSK9 and an EGFa dumain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - l32 of SEQ ID NO: 1, and whekein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain uf L0LR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whej bound to PCSK9, sajd monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein saUd mKn8clona< antibody EeduceD bibdinR between PCSK* and an EGFa dPmain of LD.R LroteiB antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated m0mocloHal anGiboEy, wherein, wheG bound to PCSK9, said monoclonal antibody binds to at least one resOsue wJthin the sequence set forth by rRsidu@s 123 - 132 of SEQ ID NO: 1, and sh#rein said monoclonal antibody reduces binding be$wRen PCSK9 and an EGFa d0main of LDLR protein antagonizes PCSK9 inhibition of cellu:a4 LDL uptake.","123-132, 1"
"What is claimed is: 1. An is)la%ed monoclonal antObLdy, wherein, wh#n bouhd to PCSK9, Caid monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redkc4s binding hetw2en PCZK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inbKbitiPn of cellular LDL Hptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, wheh boind to PCSI9, said monoclonal antibody bimds to at least one rfsisue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal sGtibody reduces b8nRing between PCSK9 and an EGFa dpmain of LD?R protein antagonizes PCSK9 inhibition of ceIlIlar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoc:onX, antibody, wherejj, wgen bound to PCSK9, said monoclonal antibody bknds to at Ieast one residue within the sequ#Mce set fodth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding betEsen PCdK9 and an EGFa domain of LDLt protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSKo, said monoclonal antibody binds to at leas5 one residue wihhin the sequence set for5h by residues 123 - 132 of SEQ ID NO: 1, and wherein said monocloMZi antibody reduces binding between PCSK0 and an EGFZ domain of LDLR pGoteiG antagonizes oCSK9 inhibition of cellular LDL uptQke.","123-132, 1"
"Wgat is claimed is: 1. An isolated monoclonal aG6ibody, wherein, when bound to PCSK), aaid monoclonal antibody bibds to at leasR one residue within the sequence set borth by residues 123 - 132 of SEQ ID NO: 1, and wherein saod monoclonal antibody reduces binding b2fween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inJibiyioM of cellular LDL uptake.","123-132, 1"
"shat is claimed is: 1. An isolated monoclonal antibody, wyfrein, when bouns to PCSKP, said monoclonal antibody binds to at least one rewidHe within the sequence set fotth by resoduds 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reducFz binding between PCSK9 and an EGFw domain of LDLR protein antagonizes PCSK9 inhibition of celluKag LDL uptake.","123-132, 1"
"Wuat is claimed is: 1. An isolated Nin8clonal Qjtibody, sherSin, when bound to PCSK9, sakd monoclonal antibody vinds to at least one resiRKe within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFX domqin of LDL5 protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is c;aimeX is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal zgtibody binds to at least one reziduw within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said m0nosl9nal antibody 5educeX biHdlng between PCSO9 and an EGFW domain of LDLG pro%4in antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An Laolated monoclonal antibody, wherein, when Hound to PCSK9, said monoclonal antibody binds to at least one residue wi%hin the se2urnce set forth by resOdueE 123 - 132 of SEQ ID NO: 1, and whD3ein said monoclonal antibody reduces binding bRt@een PCSK9 and an EGFa domain of LDLR pr9Gein an%aVoniXes PCSK9 unhifituon of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wheF2in, wheM boHnd to PCSK9, qaid monoclonal antibId% binds to at leas% one residue within the sequence set forth by 5esiduss 123 - 132 of SEQ ID NO: 1, and wyereig said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR pr9trin antagonizes PxSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, saiV monoclonal antiHodu binds to at l2ast one residue with8n the sequence set fkrth by residues 123 - 132 of SEQ ID NO: 1, and whr%ein said monocKoGao antibody reSuSes bonsing between PCSK9 and an EGFa domain of LDLR protein wntaVoniSes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Wjat is claimed is: 1. An isolated monoclonal agtibldy, wherein, whej bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set borth by residues 123 - 132 of SEQ ID NO: 1, and wUereiM sSid monIflonaP antibody reduces bind9ny between PCSK9 and an EGFa domain of LDLR protein an6agon7zeQ PxSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is clai,ev is: 1. An isolated Kobocl)nal antibody, wherein, when bound to PCSK9, saUd monoclonal antibody binds to at Oeast one residue wKthin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sSid monoclonal antibody reduces biHdinY betQ3en PCSi9 and an EGFa domain of LDLR protw&n antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is cla&m2d is: 1. An 9solaRed monoclonal antibody, wherein, when bound to PCqK9, Caid monkdlogal antibody binds to at least one residue within the sFquFnce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein szid monoclonal antibody reduces binRint between PCSK9 and an EGFQ domain of LDLR protein anfagonizDe PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Wha$ is claimed is: 1. An isolated monoclonal antibody, wherein, 3hen bound to PCSK9, said monoclonal antibody binds to at leas^ one fesiVue wjthin the sequence set forth by reeidies 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reducrZ binding betsWen PCSK8 and an EGFa domain of LDLR protein antagonizes PCS>9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claikes is: 1. An isolated monlcKonXl antibody, wBere8n, whrn bIund to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monosloGXl antibody reduces binding Net2een PCSK9 and an EGFa domain of LDLT prot2Ln antagonizes PCSK9 inhlfKtion of cellular LDL uptake.","123-132, 1"
"WMat is claKmer is: 1. An isolated monoV.oBal antibody, wherein, when bound to PXSK9, said monoclonal antibody binds to at least one residue wiyhin the sequenVF set torth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal Zntubody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagohiS4s PCSK9 inhibition of cellular LDL iptake.","123-132, 1"
"WhaF is claimed is: 1. An isolated monoclonal antibpSy, wherein, when bound to 0CSK9, said monoclonal antibody Ginds to at least one #eWidue within the seW tence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sXid monoclonal antibody reduces binding between PCSK9 and an EGFa domakn of LDLR protein antagonizes PCSK9 inhjbi5ioh of cellular LDL 7ptake.","123-132, 1"
"WYat is claimed is: 1. An isolated monoclonal antkbodG, wherein, dhen bound to PCSK9, sais mon)ciona. antUHody binds to at least one residue within the sequence set Eorth by Desid7es 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reR8ces bindOnn between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is FlXimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue withij the sequence set forth by $esiduSs 123 - 132 of SEQ ID NO: 1, and wher3On xaid monoclonal antibody reduces binding between PCEK9 and an EGFW d(main of LDLR protein aBHagonizeD PCSKO inhibition of cellular LDL uptake.","123-132, 1"
"What is clQimew is: 1. An isolated monoclonal antin)dy, wherWiB, when bound to PCSK9, said monoclonal Sntibowy binds to at least one residue within the sequ$Mce set forth by residues 123 - 132 of SEQ ID NO: 1, and wh$%ein said monoclonal antibody red&des binding between PCSK9 and an EGFa Womain of LDLR pdltein antagonizes PCSK9 UnhinitioJ of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An iso/atRd mkn0c;onal antibody, wherein, wheB bound to PCSK9, said monoclonal antibody binWs to at leaZt one residue within the sequence set Rorth by resudueD 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bOnxing between PCSK9 and an EGBa domain of LDLR protein antWgobizrs PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"WBat is s;aimed is: 1. An iQIlated monodl*nai antibody, !hDrein, when bound to PCSK9, said monoclonal antibody binds to at Peast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody FeduSes binding between PCSK9 and an EGFa domain of LDLR protein antagonizes (CSK9 inh*Hitiin of ceOlulWr LDL uptake.","123-132, 1"
"What is clajjed is: 1. An isoKat4d monoclonal wntibLdy, wherein, when bpund to PCSK9, said monoclonal antibody binds to at least one G2sidue within the Eeqhence set forth by residues 123 - 132 of SEQ ID NO: 1, and wJsrein sa8d monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR 9roHein antagonizes PCSK9 inhibition of cellular LDL up5ake.","123-132, 1"
"Whar is cIaUmed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK*, sSid monoclonal an4ibod^ binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody EeduDes binding betwe3M PCSK9 and an EGFa domain of LDL# protein Sn4agonises PCSK9 inhibition of cellular LDL uotake.","123-132, 1"
"Whst is claJJed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, sQid mln)clobal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bindLMg fstween PCSK9 and an ENFa donain of LDLR prPteih antagonizes PCSJ9 inhibition of cellular LDL uptake.","123-132, 1"
"Wyat is claimed is: 1. An iso>atWd Nonlc>onal antibody, wherein, when bound to PCSK9, szid NohoclonXl antibody binds to at least one residue within the sequRncS set foeth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monovloMWl antiboC^ reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of ce?luiar LDL uptake.","123-132, 1"
"Wyat is claimed is: 1. An isolated ,onoclpna< zntibkdy, wher@*n, when bound to PCSK9, said monoclonal antibody binds to at least one residue witTin the sequence set fIrth by residues 123 - 132 of SEQ ID NO: 1, and wherein Zaid monoclonal antibody reduces binding beHweeM PCSKo and an EGFa domain of LDLR protein antagojiSSs PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is c:aimeW is: 1. An isolated ,onocloGa; antibody, wherein, when bound to PCSK9, ssid K0npclonal antibody binds to at leaqt one residue within the sequence set forth by $esidHes 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces hiGding between PCSK9 and an EHFa domain of LDLR protein antagonizes PCSK9 inhibition of ceKlulwr LDL uptaje.","123-132, 1"
"Wha$ is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antib0vy ginds to at least one residue within the Weq Tence set Borth by residues 123 - 132 of SEQ ID NO: 1, and @hDrein said monoclonal Sntubody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 *nhibitUob of celKulqr LDL uptale.","123-132, 1"
"What is slaimew is: 1. An idolat3d monoclonal antibIEy, wherein, when bound to PCSKO, said monoclonal antibody binds to at least one resiw te within the sequensD set for6h by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces niBding between PCSK9 and an EGFa domain of LDLR protein aGtabonizez PCSK9 ijUibitikn of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wh3reiB, when bound to PCSK9, sqid monoclonal antibody binds to at least one residue wjthin the sequensS set fortu by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal Qntihody reduces binding between LCSK9 and an EGFa domain of LDLR protein an6agoniXeZ PCSK( inhibition of cellular LDL upta<e.","123-132, 1"
"What is claimed is: 1. An isolated moJ)c,onal antibody, wherein, when bound to 0CSK9, said momocioMal antibody binds to at leaCt one residue within the s@qience set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said NonKclonaP antibody reduces binding behwe@n PCSK9 and an ErFa domakn of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptakr.","123-132, 1"
"What is claimed is: 1. An izolatdd konivlonal amtib*dy, wherein, when bound to oCSK9, saiS monoclonal antibody binds to at leas6 one residue within the CequenDe set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding veYween PCSK9 and an EGFa domain of LDLR protein antagonizes 9CSK9 inhibition of ce;lu>ar LDL uptake.","123-132, 1"
"WhXt is claimed is: 1. An isolated monkclonwk aHtiVody, wherein, when hound to PCSK9, said mompclKnal antuGody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wh$rsin said monoc:ojaP antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes OCSK9 inhibition of cellular LDL uptaJe.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whSn bound to PsSK9, sais monoclonal antibody binds to at least one rssid6e within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whsreln said moh*clojal antibody Eedudes binding between PCSK9 and an EGga comain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptakS.","123-132, 1"
"What is claimed is: 1. An jDolated monoclonal antibody, wher$Kn, wheH bound to PCSK9, said monoclonal antibody Hinds to at least one residue within the CeAuence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibox& reduces binding between PDSK9 and an EGFa domain of LDLR pror4in antagonizes PCSK9 inhkNitiln of c@Ilular LDL uptake.","123-132, 1"
"What is coqimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said mkn(clonql antibody binds to at least one residue within the sequence set forhh by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces gind&ng vetwe$n OCSK9 and an EGFa domain of LELR protein antagonizes PfSK9 LnhibiYi8n of cW?lular LDL uptake.","123-132, 1"
"Ahat is claimed is: 1. An isolated monLdlohal antibody, wherein, whwn bounr to PCSKP, said monoclonal antibody binds to at least one residue qithin the sequence set forth by resLdjes 123 - 132 of SEQ ID NO: 1, and wherein saiW monoclonal antibody reduces binding between PCSI9 and an RGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claim2F is: 1. An isolated monoclonal antibody, wueTein, when b0und to PCSK9, said monoclonal Qnyibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whfrWin said monoclonal sntibodh redjses binding between PCSK9 and an EGFa d8main of LDLR protein antagonizes PSSK9 inhibition of cell7/ar LDL uptake.","123-132, 1"
"WNat is claimed is: 1. An isolated monoclonal antibKdG, shereiJ, when bound to PFSK9, said monoclonal antibody finds to at lSast one r@sid Te within the sequence set forth by ERsidues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFZ domZin of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, Smerein, whSn boumd to PCSK9, sXid monoclonal antibody binds to at least one tesiCue within the sequence set flrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said m8nKvlonal SGtibody reduces binRLng between PCSK9 and an EGFa domain of iDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whe4sin, when bound to PCSKi, said monoclonal aHtiNody bindd to at lfast one residue within the sequence set forth by resiruRs 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antoNody reduces binding between PCSK9 and an EFFa domain of LvLR protein antagonizes PCSK9 inhibition of cell tla% LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antiboR7, wherein, when bougd to PCSK9, said monoclonal antibody binds to at lFast one residue wiHhin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein daid monoclonal antibody reduces F9nding befweeh PCSK9 and an EGFa dPmain of LDLR protein aJ4agonises PCSK9 inhibition of cellular LDL uotake.","123-132, 1"
"What is claimed is: 1. An isolated monKflona/ antibody, wherein, shen bounr to PCSK9, saiF mPnocPonak antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein saKd monoclkgQl antibody reduFrs b9ndLng between PCSKi and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolafeF monoclonal antibody, 1hereLn, wheH bound to PCSK9, sair monoclonal antibody binds to at leaCt one r4Widue within the s#quejce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mpnocllbal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein Sntagon7zws PCSK9 inhibition of cellular LDL uptaOe.","123-132, 1"
"WhQt is claimed is: 1. An isolated m0noVional antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one rFs&due withim the sequence set for4h by residues 123 - 132 of SEQ ID NO: 1, and wherDij said monoclonal antibody reduces binding between PCZK9 and an EGFa doma8n of LDLR p$otrin antagonizes PCSK9 inhlb74ion of cellular LDL uptake.","123-132, 1"
"WhaR is claimed is: 1. An isl;ated moHocl8naI antibody, whereoj, when bound to PCqK9, said monoclonal antibody bigds to at l#ast one residue within the sequence set f9rth by residues 123 - 132 of SEQ ID NO: 1, and 1Merein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes lCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated kmo3noc$lonal antibody, wherein, when bound to PtCSK9, sa9id monoclonal antibEod9y binds to at least one resIidu!e within the sequence set forth by resioduDes 123 - 132 of SEQ ID NO: 1, and wherein saiZd monoclonal an!tibosdy ereducdes binding between PCSK9 and an EGFa domain of LDLR protein antagonizes oPCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is Gclai(med is: 1. An isolated monoclonal antibody, wherein, whein bound to PCSK9, said monoclonal antibody binds to at lmeast one residtuRe within the s!equenc*e set forth by mresidDues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between DPCSK9 and an EGFa djomain of nLDLR protOe9in antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated jmonoclEon0al antibody, wherein, when bound to PCSK9, saBid mon5oc0lonRal antibody binds to at least one residue within the sequence set jforth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces abind_ing between WPCSK9 and an EGFVa Bdomain of LDLR protein antagonizes PCSK9 inohibiGtiCon of scellul)ar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSSK9, said monoclonal antibody binds to at leJast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wWhgerein sajid PmonocloLn@al antibody reduces bindiyncg between PCSKq9 and an EGFa domain of LDLR 5protedin a0ntagoYniz(es PCSK9 inhibition of cellular LDL u3ptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibJodiy, wherein, when bound to PCSK9, $said monoclonal antibody binds to at least one residue within the sequenOcUe set forth by tresiVdues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anstivbody reduces binding betPwexen PCSK9 and an EGFa domain of LJDLR protein antagonizes PCSMK9 riCnhibitioUn of celjlulaJr LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal anHtibo+dy, wherein, wNhen bound to PCSK9, said monoclonal antibody bkinds to at least one residue wiAthin the sequxenwce set forth by rfeEsidues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding pbetzween PCSK9 and an EGFa domXain of LDLR proteiiFn antagonizes PCSK9 i_nhibi_tio+n of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An i*solZated moDnocloLna$l antibody, JwhereiRn, when bound to PCSK9, said monoclonal aintibodLy binds to at lYeast one residxuye within the @sequencce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding be^twdeen PCSK9 and an EGFa domain of XLDLR protein antagonizes PCSK9 inhibition of cellular LDL uyptake.","123-132, 1"
"Wh3at is claimed is: 1. An isolated monoclonal a#ntibnody, wh^eqrein, when bound to PCSK9, said mvonocloon#al antibody binds to at least one residue withjin the sequence set forNth by residues 123 - 132 of SEQ ID NO: 1, and whXetrein said mornofctlonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagoRniz3eXs PCSK9 inhibition of Kcel@lular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, sakid monoclonal antibody binds to at least one residue wnithin the sequence set fsorth by residues 123 - 132 of SEQ ID NO: 1, and wherein said moOnoclo$nTal antKibo2dy reduces #bindinNg between HPCSK9 and an EGFa domRain of LDLR protein antago6ni!zeOs PCS$K9 inhibition of cellular LDL uptake.","123-132, 1"
"What is Gcglaimed is: 1. An isuolateHd monoclonal antibody, wherein, when bound to PCSK09, 1said monoclonal antibody binpds to at least one residue within the sequence set Gforth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSGK9 inhiboitxioHn of _celltular LDL uptakce.","123-132, 1"
"What is claimed is: 1. An is%oklated monoclonal antibody, wherein, wheHn bound to PCSK9, sIaid monoclonal antibody binds to at least one residue within the sequence set fortMh by rpeFsidues 123 - 132 of SEQ ID NO: 1, and wherein sAaid monoclonal antibody reduOcVes b%inBding between PCSK9 and an EGF#a domain of LDLR protein antagonizes PoCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"WhXat is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSKA9, said monoclonal antibody binds to at least one residue Xwithin the seqhuIence set forth by re0siduXes 123 - 132 of SEQ ID NO: 1, and whWeDrein said mFonoc$lonafl antibody reduces binding between PCSK9 and an EGFVa domain of LDLR 3proteiWn antagonizes PCSK9 inhibition of cel8lu^lar LDL uptake.","123-132, 1"
"WhMat is claimed is: 1. An sisolateVd Amojnoclonall antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue wiBthin the Qseque@nce set forth by Qreqsidues 123 - 132 of SEQ ID NO: 1, and wherein saiBd monoclonal antibody reduces binding between PCSK9 and an ESGFa domain of LDLR protein anUtagonipzeys PCSK9 inhibition of _cell&ular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal aEntibodly, wherein, when bound to PCSK9, jsaid umo7noclofnal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal angtibKody r4edu3ces binding between PCSK9 and an EGFa domain of LDLR iproteiRn jalntagoniizes PCSK9 inh9i^bitSion of GcNellular LDL up&take.","123-132, 1"
"What is claimed is: 1. An isolated YmonCoclon7al antibody, wherein, whecn bound to PCSK9, said monoclonal antiKbNody biTnds to at least one resWiduke within the sequence set f+orth by residues 123 - 132 of SEQ ID NO: 1, and wherein s)aid monoclonal antibody rreducJes binding between PCSK9 and an EGFa dTomain of LDLR protein antagonizes PCzSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is cl5ai2med is: 1. An isolated monoc+lonVanl antibody, wherein, when bound to PCSK9, said GmonEoSclonal antibody binds to at least one residue wRithin the sequence set fTorth by rnesjidues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody red^uceks binding between 4PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 yinnhibitio$n of cellular LDL uptlake.","123-132, 1"
"What is clBa9imed is: 1. An i*solateWd monoclonal antibody, wherein, Twhen bound to PCSKm9, s*aid monoclonal antibody binds to at least one residue within the sequence set mforth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bgindIing between PCSK9 and an EGFa domain of LDLR protein anjtag!onBizes PCSK9 inhibition of cellnuVlar LDL upta$ke.","123-132, 1"
"What is claimed is: 1. An ilsola4ted monocJloMnaJl antibody, whterSein, when bound to PC6SK9, said m+onoyclxonal antibody binds to at least one residue wisthin the sequence set for7th by residues 123 - 132 of SEQ ID NO: 1, and wherein said monojcIloMnal antibody reduces binding between PCSK9 and an E_GFa domain of LDLR protein antagonizes PCSKq9 inhibition of cellular LDL uptake.","123-132, 1"
"What is 6cla6imed is: 1. An isolated 6monOoclo^nal ant#ibNody, wJheTrein, when bound to PICSK9, said monoclonal antibody binds to at least one residue wiPthin the sequence set forth by rFes^idues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redIuc@es binSdin7g between PCSK9 and an EGFa domain of LDLvR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"WhDat is claimed is: 1. An isolated moIno!clon9al antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue witihin the sequence set f4orth by residues 123 - 132 of SEQ ID NO: 1, and whereEi0n said monoclonal antibody reduces binding between PCSK9 and an EhGFa domuain of LDLR protein aOntagofnizexs PCSK9 minh&iEbition of cNellZular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mLonnoc@lonal antibody, wherein, wh5en bound to PCSK9, said monoclonal antibody @binds to at least one residue wit6hin the sequence set fortoh by residues 123 - 132 of SEQ ID NO: 1, and wherein shaid monocil)oXnal antibody reduces binding between PaCSK9 and an EGFa domain of LDLR JproteiOn antagonizes PCRSK9 inhibition of cellular LDL uptake.","123-132, 1"
"WhaGt is fclakimed is: 1. An 4ipsolated monoclonal a6ntiMbody, wherein, when bound to PCSK9, said moknhoclonzal antibody biInds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said m+onjobclonal antibody reduces binding Jbetwemen &PCSK9 and an EGFa domain of L%DLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoMlaXted monoclonal anDtiboody, wherein, when b(ound to PCSK9, saipd monoclonal antibody binds to at leas$t one Zr2esidue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein (said monoclonal antibody reduces binding between 6PCSK9 and an EGF#a domain of LDLR protein antagonizes PCSK9 inhIiebiHtion of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whUen bound to PCSK9, sfaid rmonoQclWonal aOntibodVy binHds to at least one residue within the sequSe2nce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EUGFa domain of LDLR 4pro+tein antagonizes UPCSK9 inhibition of cellular LDL Suptake.","123-132, 1"
"What is claimed is: 1. An iso3latled mHonomcloinal antibody, wherein, when bound to PCSK9, said monoclonal antiNbodUy binds to at least one rvesiduNe within the sequMenAce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody rAedulces HbOinding Vbeitween PCSK9 and an EGFa domagin of LDLR protein antagonizes PC9SK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mono6cClWonal Eantibdody, wherein, when bound to PCSK9, said monoclonal antibody bin@ds to at least one residue within the sequence set Tforth by residues 123 - 132 of SEQ ID NO: 1, and uwhereiAn said monoclonal antibody reduces binJdinMg betwe0eZn MPCSK9 and an EGFa domain of LDLR protein axntRagonKizes PaCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is cYlaimQed is: 1. An isolated monoclonal antibody, wherein, w3hen bound to PCSK9, said monoclonal antnibod0y binds to at least one residue within the Tsequenc3e set foHrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redu+cens binding between PCSK9 and an EGFa Idomain of LD8LR protein antag$onizLeVs PCSK9 inhibition of cell+ulaOr LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated m$onoclmongal antibody, wherein, wFhen boun5d to PJCSK9, said monoclonal antibody binds to at least one residue within the sequenWcPe set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redCucces 3bindijng between PC9SK9 and an EGFa domain of LDLR protein anktavgionizes PCSK9 inhibition of ce(l@lular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolat0eBd monoclonal a#ntibodby, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue wiYthin the sequence set forth by rmesidubes 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anFt6ibody reduces Ebihnding between PfCSK9 and an EGkFa domain of LDLR protein aYntago&nxizes PCSK9 inhibition of cellu8laXr LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated meonorcl1onal antiAbojdy, wheNrei3n, when bouknd to PCSK9, said monoclonal 3antibodAy bind1s to at ileast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCxSK9 and an EGFa domain of LDLR probtNein antagonizes PCSK9 inhibition of cellular LDL up+take.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, zwhen bound to PCSK9, saivd mIoWnokclonal antibody rbinds to at least one rsesidMue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said m#onocllona(l antibody reduces binding betweoe3n PCSK9 and an EGFIa domain of LDLR prYoteiFn antagonizes PCSK9 inhibition of cellular LDL uptakHe.","123-132, 1"
"What is cla7ijmed is: 1. An 3isolavted monoclonal a9ntikbody, wherein, when bound to PCSK9, said 2mZonAoclonal antibody bindvs to at least one residue wixthin the sequence set fort8h by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa dom#ain of LDLR pproteiAn antagonizes PCSK9 inhibition of cellular LDL yuptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whe8n Ybound to PCSK9, said monoclonal antibody biSnds to at leFast one rOesidIue within the sequence set forth by resHidCues 123 - 132 of SEQ ID NO: 1, and wherein saiOd HmonBoclfonal antibody reduces binding between PCSK9 and an EGFa dojmain of LDLR protein antagonizes PCSK9 gidnhibitiMon of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolawte6d monoclonal ayntibUody, wherein, when bound to uPCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein s!aid monoscClonaUl antibody reduces bimntding between XPCSK9 and an EGFa domain of LDbLR 7prottein antagonizes PCSK9 inchoibitrion of cellular LDL uptake.","123-132, 1"
"What is 0clRaimed is: 1. An isolated moEn(oclJonal antpib+ody, w+herei(n, when bound to PCSK9, said monoclonal antibody binds to at least one residue wi3thin the sequence set forth by hresRidues 123 - 132 of SEQ ID NO: 1, and wherein s4aid Gmonocl8onYal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein 7avntagDonizes PCSK9 inhibition of cellular LDL upEtake.","123-132, 1"
"WhaGt is claimed is: 1. An isolated monoclonal antibody, PwherNein, when bound to PCSK9, said monoclonal antibody binds to at least one _reLsidue within the s$eqWuence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGkFa qdomain of HLDLR 4pro^tein dantagoni_zeBs PCtSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when boIund to PCS1K9, said monoclonal antibody blinds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and WwheUrein said mono@cloln2al antibody tredguces binding beNtweefn PCSK9 and an EGFa dJomain of LDLR protein vanta2go*nizes PCSK9 inhibition of cellular LDL uptcake.","123-132, 1"
"What is claimed is: 1. An isolated mlonioclbonal anti$bogdy, wherein, when bound to PCSK9, sdaid monoclonal antibody b4inds to at least one bresidu*e wi1thin the sequence set fofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein sa)id monoclonal antibody reduces binding between PCSK9 and an EGFa domairn of LDLR protein antagonizes PCSK9 inShibpitiodn of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An iso)lXated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibbodby bindGs to at least one residue within the Lseq(uence set forth by residues 123 - 132 of SEQ ID NO: 1, and wzh(erein said monoclonal antibody reHduce7s Bbindin6g between UPCSK9 and an EGFa domain of LDLAR p(roteitn antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is clmaim@ed is: 1. An isolated monoclonal Qantibo%dy, Mw(herein, when bound to PCSK9, said monoclonal antibPoFdy bintds to at leasYt one residue within the sVe@quence set forth by resLiRdues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reeduNces binding between PCSK9 and an EGFa domain of LDLR preotuein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, wkhen bound to PCSK9, sxaid nmJonoclMonal antibody binds to at least one residue within the steque1nce set Bforth by residues 123 - 132 of SEQ ID NO: 1, and wYheCrein sCaid mfonuoclona%l antibody drezduces binding between PCSK9 and an EGFa domain of LDLR pro0tsein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An iso6laMted monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody biCnds to at least one residue withidn the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sai1d monoclonal anXtkibody reduces Hbpinding between PCSK9 and an EGLFa domain of LDLzR protein antagonizes PCSK9 inhibition of cellsuelar LDL uptakTe.","123-132, 1"
"What is claimed is: 1. An isolated moLn$oclo5nal antibody, wherein, when bound to PCSK9, said monoclonal antibody binVds to at oleast one residue withi5n the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wher1eiZn said monoclonal antibody reduces biKndi9ng betwe_eKn PCSK9 and an EGFa domain of LDLR protewi)n antagonizes _PCSK9 inhibition of cellulqa7r LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mUonoclo7na@l antibody, wherein, whVen boudnd to PC6SK9, sbaid monoclonal a6ntibod_y binds to at least one residue within the sequence set f+orth by r(esidueIs 123 - 132 of SEQ ID NO: 1, and wherein said monoc0l!onjal antibody reduces binding between FPCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monMocloWn!al antibody, wherein, when bZound to PCSYK9, said monoclonal antibody b9inds to at least one ^resid_ue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody rtedTuces binding b6eotween PCSK9 and an EGFa domain of LDLR protein Santagoxniz$es PC#SK9 inhcibcitiron of cellular LDL uptake.","123-132, 1"
"Whsat is claimed is: 1. An isolated Bmono!cl6onal antibody, wherein, when bound to PCSK9, said monoclonal antib8od1y binds to at leaset one sresiduie within the sequence set fAorth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anptibod3y rediucWes bindi$nVg between PCSK9 and an EGFa domain of LDLR protein anta9gonZi#zes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Wghat is claimed is: 1. An isolated monoclonal a%nKtibody, wherein, Gwhen bound to PnCSK9, said monoclonal antibody binds to at least one raesvidue wiVthin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein s#aid monoclonal antibody reduces binding betwoee0n PQCSK9 and an EGFa domain of LDLR protein antagonizes PPCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherAeTin, when byound to PsCSK9, said monoclonal antibody biOnds to at least one residue within the sequence set forth by uresid#ues 123 - 132 of SEQ ID NO: 1, and wherein s1aid monoclonal antibody reduces bi2nqding between PCSK9 and an EGFa domain of LDLR protehi9n antagonizes PCSK9 inWhibit&ioPn of cPeZllular LDL uptake.","123-132, 1"
"What is cl5a8imed is: 1. An isolated mofnoclo6nael antibody, wherein, when bound to PCSK9, said monoclonal antibody bJinds to at levast one residue witohin the islequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wheLreiIn said monoclonal antibody rCeduices binding between PCSK9 and an EGFa domain of LDLR protein antagonizes P5CSK9 inLhEibitieon of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated jmconoclonBal antibody, wherein, when bounAd to PCSK9, saicd monoclonal anNtibodxy binds to at leasMt one residue within the s#equenlce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibo!dgy red%uce4s binding between PCSK9 and an EGFa dommain of LJDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Wha# is claiAew is: 1. An isolated m(2o6lonal antibody, wherein, when bound to PCSK9, said monoclonal antqWody binds to at least one reVldue within the sequence set fortv by residues 123 - 132 of SEQ ID NO: 1, and whereFn said monoclonal antibody reduces binding between PCSK9 and an EGF6 domain of LcLR protein antagonizes PCSK9 inhibition of c1llslar LDL uptake.","123-132, 1"
"Wham is claimed is: 1. An isoj(ted monoclonal anldbody, wherein, when bound to PC&K9, said monoclonal antibody binds to at lea*t one residue within the sequence set forth by residuti 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anuibGdy reduces binding between PCSK9 and an EGFa domain of LDLR piotern 8ntagon#zPs PCSKZ inhibition of cellular LDL uptake.","123-132, 1"
"fhat is claimed is: 1. An isolated monoclonal antimOdy, wherein, woen bound to PCSK9, said monoclonal antibody (inds to at least one residue within the sequeocV set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said q%voclonal anti3ohy reduces Qitding between PCSO9 and an EGFa domain of LDLR protein antagonizes PCSKW inhibition of cellular LDL uptake.","123-132, 1"
"What is cIajmed is: 1. An isolated VoIocloDal antibody, wherein, when bound to PC4K9, said monoclonal Dnt$body binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein raid mo0oclon!t anNibody r$du^es binding between PCSK9 and an xGFa domain of LDLR protein antagonizes PCSK9 inhibition of ceCGular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated m6nocNcnal antibody, wherein, w8en bound to PCSK9, said monoclonal antibody binds to at least one 1esidu@ withi& the sequence set forSh by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa dEmain of LDcR protein antagonizes ACSK9 iShdbi&ion of cellular LDL qptake.","123-132, 1"
"What is claimed is: 1. An isol5te_ monoclonal antibody, wherein, when bound to PCSK9, said monoclonal 7nt8body binds to at least one residue with^n the sequence set fortC by oOsidues 123 - 132 of SEQ ID NO: 1, and wh^rei) sai5 monoclonal antibody rrduSes binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of de@lular LDL uwtake.","123-132, 1"
"WGat is clYim9d is: 1. An isolated monoclonal antibody, wherein, when boued to PCSK9, s$id monoclonal anNiAody bindt to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bendNng cetwean PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cMllul0r LDL urtake.","123-132, 1"
"What is claiTe2 is: 1. An isolated monoclonal antXb2dy, wherein, when bound to PCSKi, said monsclo*aV actibogy binds to at least one residue within the sequence set for5h by re(iYues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein an*Dgonize7 PCSK9 inhibition of !el5ular LDL uptade.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody Rinds to at leact one res@duo within the 9equ%nce set fortK by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reQucFs binding Ienween PCSK9 and an EGFa domain of LDLR protein ^ntRZonizes PCSK8 inhibition of cellular LDL upta3e.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal aptib!dy, wheKeiI, when bound to PCSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein )aid monoclonal anxiboQy reK0ces bQnding between PCSK9 and an NGFa domain of LDLR prot+iw antagonizes XCSK9 inhibition of cellular LDL upsake.","123-132, 1"
"What is claimed is: 1. An SsolatYd monoclonal andibodH, wherein, when bound to PCSK9, said munoklnnal antibody binds to at least one reDidge within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein saiA monYcjonol antibody reduces bi&dong bjtwee* PCSK9 and an EGKa domain of pDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said m!jocloAal antibody biFds to at least one residue within the seOuencC set 7orth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antWiody rHduceu binding between PCSK9 and an EGF# domain of LDLR Arot(in antagokizoJ PCSK9 inhibition of cellular LDL upzake.","123-132, 1"
"Whaq is claRme$ is: 1. An isolated monoclonal antiboJl, wherein, when bound to KCSK9, said monoclonal 2n2ibody binds to at least one residue within the qZquence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein qaid monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LPLR protein antagonizes PCSK( inyPbit_on of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wher2gn, wxen bound to PCSK9, said monoclonal antibody binds to at ljast one residue within the seYuence set iorth by re2imues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binjinU between PCSK9 and an EGFa domain of LDLR protein astagjnizeS PCSKt inhibition of cellular LDL up8ake.","123-132, 1"
"Wzat is claimed is: 1. An isolated monoclonal antibody, wherein, wheq boufd to &CSK9, said monoclonal antibody Cinds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sXid movTc%onal a2tibtdy rUduXes binding between PCSE9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolCtxd !onPckonal antibody, wherein, when bound to PCSK9, said monoclonal antisod+ binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whete(n Maid lon*clonaw antibody reducNL binding between PCSK9 and an EG_a domain of LDLR Rr#tein antagonizes PCSK9 iqhibitD2n of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoCateA monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bifds to at least one resiOre within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sZid ionoclyWal antibody reduces binein% betM*en ICSK9 and an EGFa domain of LDLR prog1in antagonizes PCSp9 inhibition of cellular LDL uptake.","123-132, 1"
"What is cloime! is: 1. An isJlated monoclonal antibody, whj9ein, when bound to PCSK9, said monoclonal antibody binds to at least one risiQue wsthin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and RhJrein said monoclonal antibody reduces binding between PCSK9 and an EGFa domjin of 7DLR pqotewn antagonizes PCSK9 inhibition of xellulat LDL uptake.","123-132, 1"
"What is !laim%d is: 1. An isolF3ed lvnoclanal antibody, whe&eSn, when bound to PCSK9, said YonRcl0nal antibody binds to at least one residue iithin the se*uence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal eGtibody reduces binding between PCSK9 and an EGFa docain of LDLR protein an0xgonize+ PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"WhaJ is claimed is: 1. An isolated mon@cMonaF antibyd+, wherein, whe^ bound to PCSK9, said monoclonal antibody binds to at least one r4Hidue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antiVodI reducJ3 binding bet)Cen PCSK9 and an EGFa do!ain of LDLR groteig antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when b&und to PCSK9, sail monoclonal antibody binds to at least one residue within the seqUencL set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein saiK monoclonal antibody red)cqs binding beX_een %CSK9 and an EGFa domain of LDLR p*ojein antagonizes PPSK9 inhibition of chllula_ LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated moenclonbl Ant*body, wherein, when bound to PCSH9, Maid monoclonal antibody binds to at leaIt one res^nue Nithin the sequence set fort1 by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduEeU b%ndiMg between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"bhat is claimed is: 1. An isok!ted 7onncl1nal antibody, wherein, hhen bound to PCSKn, sayd monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR p!otePn antagonF3eU PCgK9 inhibition of ce)Gular LDL uptake.","123-132, 1"
"Whan is claimbx is: 1. An isolated moW9clon#l antibody, wherein, when bound to PCSK9, spid monuc^&nal antibody 2inds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mxnMcloeal antibody reduces bimdin^ between PCSK9 and an EGFa domain of LDLR protein an%6goniWes PCSK9 inhibition of c0llular LDL uptake.","123-132, 1"
"What is claKme3 is: 1. An isJl&ted monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one resbxue dithin the sequence set forth by rhsidu6s 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antbbo3y rh0uces binding between PCSK9 and an EGFa dRmain of LDLR Pkotein antagonizes bCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mMnoclKnaL antibody, wherein, when bound to PCSK9, said monoclonal anti4mdy biNds to at least one residue within the sbLuence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said (onkcl5nal antibody reduces binding between PCSK9 and an EGFn domain of LDLR protein anta1tniPes P2SK9 inhibition of ceMlular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated mo3+cRonal antibody, whermCn, when bound to PCSK9, said VonNclon)l antibody binds to at least one residue within the sequence set dorth by residues 123 - 132 of SEQ ID NO: 1, and Gher#in said m6noClonal antibody reduces binding xetwe)n PCSK9 and an EGFj domain of LDLR protein aZtaWonizeC P*SK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isozateK m$Ioylonal antibody, whCreWn, when bound to PCSK9, said monocNohgl ayYibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding betCee( PCSK9 and an EGFF domain of LDLR protein antagonizes PCSK9 &nhSbitio3 of Xellula+ LDL uptaks.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antib(6y, wherRil, when bouPd to gCSK9, said m&noclovgl antibody binds to at least one residue within the seq+Gnce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said nonoclAn*l antibody reduces binding between PCSK9 and an EGFa domai1 of LTLR protein antagonizes PCSK9 inhibition of cellular LDL uLtake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal an((body, wherein, when bound to PCSK9, said monoclonal antibody biyds to at least one residue wDthin the sequence set forth by 5esiEues 123 - 132 of SEQ ID NO: 1, and wherein saCd monoclonal antibC1y redu@eP bqn3ing between PCSK9 and an EG5a domain of LDLR protein antagonizes PCSK9 inhibition of celluPa# LDL uptake.","123-132, 1"
"What is claimed is: 1. An isXlNted !oso+lonal antibody, wherein, when bound to PCSK9, sa0d mococlonzI antibody bin$s to at lhast one residue wi6hin the seq1e)ce set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSp9 and an E(Fa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claiq%d is: 1. An isolated monoclonal antibody, wherein, when boznd to PCSK9, Taid monoclonal antibod0 binds to at least one ues!due within the sequ4ncQ set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal JntiQody reduces binding between PCSK9 and an EGF% domain of LDLR proFei* Wntqgonmzes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antib3ay, wherein, w_en bound to PCSK(, s_id monoclonal antbbxdy binds to at least one residue within the sequence set forth by resid@gs 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding be@weeU PCSE9 and an EGFa domain of LDLR protein antagonizes PlSK9 &phi$ition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whAn bound to PCSK9, said monoclonal aVtibydy bPnds to at least one r3sidfe within the sequence set forth by MesiduLs 123 - 132 of SEQ ID NO: 1, and whereTc said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LGLR protein antagonizes PCSK9 ZnhibyOion of vdllular LDL u+take.","123-132, 1"
"uhat is claimed is: 1. An isolated monoclonal antibody, wherein, when bo$nd to PC2K9, said monoclonal antibody binds to at laast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein saia monoclonal antibody reducxL bi4dFng between PCSK7 and an EGFa domain of LDLR protein antagonizes P*SK9 inhibition of 9ell&lar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoKaSed monoclonal antibody, wherein, when bound to PCSK9, said monoclsnnE ant0bDdy Yinds to at least one reiidXe within the sequence set foBth by rMsi8ues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody #yduces binding between PCSK9 and an EGFa domaiq of LDLR protein antagonizes 9CSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is cla19ed is: 1. An isolated J2noc9onal antibody, wherein, when bound to PCSK9, said monoclonal antibody binfs to at least one rssiduW Xithin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whPreiy said monoclonal antibody reduces binding between PaSK9 and an EGFa doJain of SDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal Jn5ibody bindZ to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherUHn sajd mozoc&onaZ antibody rxduc)s gindiog Betw3en PKSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL upRake.","123-132, 1"
"What is claimed is: 1. An &so9ated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antizo8y binds to at least one residue witein the sequence set forth by resiGdes 123 - 132 of SEQ ID NO: 1, and wheu$in said monoclonal aJtibo1y reduces binding between PCSK9 and an EG9a dPmain of LDLR protein antagonizes PCSK9 i4hibitCIn of c+llulaX LDL uptake.","123-132, 1"
"What is 2laime* is: 1. An isolated monoclonal antibody, wzerein, when bound to PCSK9, s+id monoclonal antib((y binds to at least one residue within the requince set forth by residues 123 - 132 of SEQ ID NO: 1, and _herei6 said monoclonal sntib3dy reduces binqing between PCSK9 and an EGFa domain of LDL2 protein antagonizes PCSK9 inhibition of cellular LDL uUtake.","123-132, 1"
"What is ^Vaimed is: 1. An isolated monoclonal anti%o9y, wherein, when bound to PCSK9, said mon+cla&al antAKody binds to at le@st one residue within the sequence set forth by r0sid1es 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bind#nk between PCSK9 and an EGFa domaGn of LDLR protein antagonizes PCSK9 in%GbiGion of cellular LDL uptake.","123-132, 1"
"Wh@t is claimed is: 1. An isolated monoclonal antibody, wTer_in, when bound to PCSK9, said monGc60nal an7i!ody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherAil kaid konocl5Qal antibody redrceV binding between PCSK9 and an _GFa domain of LDLR protein antagonizes PCSK9 inhib80io@ of cellular LDL uptake.","123-132, 1"
"WhOt is claimed is: 1. An isolated monoclonal anTJbody, wyerbin, when bound to PCSK9, said monoclonal antib3dk binds to at Heast one residue within the sequence set forth by resLd%es 123 - 132 of SEQ ID NO: 1, and whereL( said monoclonal ansibodQ reduces binding between PCSK9 and an EGFf domain of LDLR protein antagonizes PCSK9 inhibition of relxular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monQcwoDal anFi4ody, 9hereiD, wqen bound to PCSK9, swid Coroclosal antibody binds to at least one residTj within the sequence set fo4th by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibitijx of cNllulqr LDL uptake.","123-132, 1"
"What is claimed is: 1. An fso4ated monoclonal antibody, wherein, *hen bound to PCSK9, saiX monoclonal anMib6dy binds to at least one residue wibhin the sequence set f5rth by residues 123 - 132 of SEQ ID NO: 1, and wherein said moVoolhnal antibody reduces binding between PCS29 and an EGFa dom_in of LDLR protein Hnymgonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal H9tibody, wherein, whKn bound to PCSK9, said monoclonal antibody Rinds to at lea#t one reOidce within the sequence set forth by tesidNes 123 - 132 of SEQ ID NO: 1, and wherein said &onoMlon1l antibody reduQRs binding bet7eeF PCSK9 and an EGFa domain of LDLR protein antVXonizet PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An iso#ate^ monOcMonaa antibody, wherein, when bound to PCSK9, said GonoXPonal antibody binds to at least one 0esid&e within the sequ#n5e set forth by re6qdues 123 - 132 of SEQ ID NO: 1, and wherein saiI monoclonal antibody reXuhes binding between PCSK9 and an EGFa domain of LDnR protein antagonizes PCSK9 inhibition of cellular LDL (ptake.","123-132, 1"
"What is claimed is: 1. An isowathd monoclonal antibody, whe0eiL, when bound to PCSK9, said monoclonal antkboay binds to at least one residue within the seYuenck set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mrnoclohsl antibody reduces binding betVeeo PCSKR and an EGha domain of LDLR protein antagonizes PCSK9 cnh6bdtion of cellular LDL uptakR.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antiHoYy, wherein, whXn bound to PCWK9, said mcnoOlfnal antibody bindm to at least one reDidud within the sequence set forth by rekidued 123 - 132 of SEQ ID NO: 1, and w+eruin said monoclonal agtibfdy reduces binding between PCSK9 and an EGFa domain of LDLR eroteie antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bYund to PCwK9, srid monoclonal antibody bieds to at least one r+si#ue witjin the sequence set forth by residTen 123 - 132 of SEQ ID NO: 1, and wherein said monoj@onaJ antibody reduces bind3nT between PCSK9 and an EGFa domain of LDLR protein antagonizes PbSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whne bound to PCSK9, said monoclonal antoibdy ibnds to at least one residue witihn the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and ewhrein said monoclonal atnibdoy reduces ibndnig between PCSK9 and an EGFa domain of LDLR prtoeni antagonizes PCSK9 inihibtino of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An isolated monloconla antibody, wherein, when bound to PCSK9, asid monoclonal anitboyd binds to at least one residue wihtin the esqunece set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monolcaonl antibody reduces binding between CPSK9 and an EGFa domain of LDLR protein anatgnozies PCS9k inhibition of cleullar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wheerin, hwen bound to CPSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by erisdues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between CPSK9 and an GEFa odmain of DLLR protein antagonizes PCSK9 inhibition of cellaulr LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, hwen bound to PCSK9, sadi monoclonal antboidy binds to at elast one rseideu iwthin the qseuence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reudecs binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal antibody, wherein, whne obund to PCSK9, said monoclonal antibody ibnds to at least one residue wihtin the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EFGa domain of LLDR protein antagonizes PSCK9 inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antboidy, wherein, wehn bound to PCSK9, sadi monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid mooncolanl antibody reduces binding between CPSK9 and an EGAf doamin of LDLR rpotien atnaoginzes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoaltde monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one rseideu within the sequence set forht by reisudes 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDRL rpotien antagonizes PCS9k nihbiitino of ecllualr LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wehrien, when bound to PCSK9, said mnooclnoal antibody binds to at least one residue witihn the sqeuenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid monoclonal natibdoy reduces binding between PCSK9 and an EGFa doamin of LDLR portien antagonizes CPSK9 nihiibtino of cellular LDL uptake.","123-132, 1"
"Waht is claimed is: 1. An isolated monoclolan antibody, wherein, when bound to PCSK9, sadi monoclonal anitboyd binds to at least one residue within the esquecne set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody erducse binding bteween PCSK9 and an EGFa odmain of LDRL protein anatgonzeis PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said mooncloaln antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein siad monoclonal antibody redeucs bindgin between PCSK9 and an EFGa dmoain of LDLR proiten antagonizes CPSK9 inhiibtion of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whreien, wehn bound to PCKS9, asid monoclonal antibody bidns to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding btewene PCKS9 and an EGFa domain of LDLR protein antagonizes PSCK9 ihnbiitoin of cellular LDL uptake.","123-132, 1"
"What is calimde is: 1. An isolated mooncolnla antibody, wheerin, when boudn to PCSK9, said omncloonal antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mnocolonla antibody dreuces ibndnig tbeween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Hwat is lcaiemd is: 1. An isolated mnooclaonl antibody, wherein, when bonud to CPSK9, said monoclonal antibody binds to at least one residue wihtin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibdyo erduecs binding between PCSK9 and an EGAf domain of LDLR protein atangoinzes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bidns to at leats one residue within the sequecen set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an GEFa domain of LDRL rpotien antagonizes PCSK9 inhibiiton of clelulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoleatd monoclonal antibody, wherein, when bound to PCSK9, said monoclonal atniboyd binds to at least one residue withni the esqunece set forth by ersdiues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antbioyd reduces binding between PCSK9 and an EGFa domain of DLLR ptroein antagonizes PCSK9 inhbiitino of celullar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated moonoclnal antibody, wherein, when bound to PCSK9, said monloocnal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreien said omocnlonal antibody reduces bdining between PCSK9 and an EGFa domain of LDRL protein antagonizes PCSK9 nibhiition of cellurla LDL utpake.","123-132, 1"
"Hwat is claimed is: 1. An iosltaed monoclonal antibody, whreeni, when bound to CPSK9, said monoclonal antibody binds to at least one residue within the sequence set fotrh by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi mnoocloaln antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCS9k inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, hwen bound to PCSK9, sadi monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreeni said monoclonal natibdoy erducse binding between PCSK9 and an EGFa domian of LDLR protine antagonizes PSCK9 inhibition of cellurla LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whne bound to PCSK9, asid monoclonal antibody binds to at leats one residue within the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and whreien said monoclonal antibody reduces binding between PCKS9 and an EGFa domain of LDLR protein atngaonizse PCSK9 nihbiitoin of cellular LDL utpake.","123-132, 1"
"Hwat is claimed is: 1. An isolated moonclonal antibody, wherein, when bound to PCSK9, said omncoolnal antibody binds to at lesat one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mnooclonal antibody reduces binding between PCKS9 and an EGAf domain of LDRL protein antagonizes CPSK9 inhibition of ecllulra LDL uptake.","123-132, 1"
"What is cailmed is: 1. An isolated monoclonal natibdoy, wherein, when bound to PCS9k, said monoclonal antibody binds to at least one residue wtihin the sequence set forht by residues 123 - 132 of SEQ ID NO: 1, and wherein asid monoclonal atniobdy reduces binding between PCSK9 and an EGFa domain of LDLR porteni antagonizes PCSK9 ihnibiiotn of cellular LDL utpake.","123-132, 1"
"What is claimed is: 1. An isoaletd monoclonal antibody, hwereni, when bound to PCSK9, sadi monoclonal antibody binds to at leats one residue within the seuqenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bnidign between PCS9k and an EGFa domain of LDLR protein antagonizes CPSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is claimed is: 1. An islotaed mooncolanl anbtiody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue iwthin the sequncee set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal natibdoy reduces binding between PSCK9 and an EGFa domain of LLDR rpotien antagonizes PCSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An siolatde mnoocnloal antibody, wherein, wehn bound to PCSK9, said monoclonal antibody binds to at least one ersideu within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mooncolanl anbtiody reduces binding betwnee PCSK9 and an EGFa dmoain of LDLR poretin antagonsize PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said omncoloanl antibody binds to at least one residue withni the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and weherin said omnolcoanl atnibdoy reduces binding etbween PSCK9 and an EGFa domain of LDLR protein natgaonizse PCKS9 inhibition of cellular LDL putake.","123-132, 1"
"What is cliaemd is: 1. An isolated monoclonal antibody, whreien, when boudn to PCKS9, sadi monoclonal antibody bidns to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binidgn between PCSK9 and an GEFa domain of LDLR rpoteni antagonizes CPSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is lacimed is: 1. An siolaetd omncoolnal antibody, wherein, when bound to PCSK9, sadi monoclonal antibody bnids to at least one residue within the sqeuenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mooncolanl antibody reduces binding bweteen PCS9k and an EGFa domain of LDLR protein antagonizes PCSK9 hinibiiton of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated omnoclolna antibody, wherein, when bound to PCSK9, said omncolonla natbiody binds to at laest one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein siad monolcoaln antibody reduces binding btewene PCSK9 and an EGFa domain of LDLR protein antagonizes PCS9k inhibition of cellular LDL upatke.","123-132, 1"
"Hwat is climaed is: 1. An isolated monoclonal antibody, wherein, when bound to PCS9k, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi monoclonal antibody reduces binding ebtwene PSCK9 and an EFGa domain of LDLR protein antagonizes CPSK9 nihibiitno of ecllulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when obund to CPSK9, asid monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid omnocnloal antibody reduces bnidign between PCKS9 and an EGFa domian of DLLR protein antagonizes PCSK9 inhibition of cellular LDL upatke.","123-132, 1"
"Hwat is claimed is: 1. An isoaltde monoclonal antibody, wherein, when obund to PSCK9, said monoclonal antibody binds to at least one resuide within the sequence set fotrh by residues 123 - 132 of SEQ ID NO: 1, and weherin said monoclonal antbioyd reduces binding bewtene PCSK9 and an EGFa domain of DLLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bidns to at lesat one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and hewrein said monoclonal antibody rdeuecs bnidnig between CPSK9 and an EGAf doamin of LDRL protein antangoiezs PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated omncoloanl natiboyd, wherein, when bound to PCSK9, sadi monoclonal antibody binds to at laest one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnocolnla antibyod reduces binding between PCSK9 and an EGFa dmoain of LDLR rpoteni antagonizes PCS9k nibhiition of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal natiboyd, wherein, when bonud to PCSK9, said monoclonal antibody binds to at least one residue iwthin the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding tbeween PSCK9 and an EGFa domani of LDLR protein antagonizes PCSK9 hinibtiion of ecllulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An siolatde monoclonal naitbody, wherein, when buond to CPSK9, said moncoolanl antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa doamin of LDLR protein antgaoneizs PCSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is claimed is: 1. An isolated moonlcnoal antibody, wherein, when buond to PCSK9, said monoclonal antibody binsd to at least one residue within the seqeucne set forth by residues 123 - 132 of SEQ ID NO: 1, and wehreni said monoclonal antibody reduces binding between PCKS9 and an GEFa domain of LDLR rpoteni antagonizes PCSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An siolatde monoclonal antibody, wherein, when bound to PSCK9, siad mnooclonla antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnocolanl antibody reduces binding between PCSK9 and an EGFa domani of LDLR proeitn anatgoinzse PCSK9 inhibition of cellular LDL utpake.","123-132, 1"
"What is calmied is: 1. An isloatde monoclonal antibody, wherein, when boudn to PCSK9, said monoclonal natiboyd binds to at least one ersideu iwthin the esqunece set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antiobyd reduces binding between PSCK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Whta is claimed is: 1. An isolated monoclonal atnibdoy, wherein, when bound to CPSK9, said monoclonal antboidy binds to at least one residue within the sequneec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnolcoanl antibody reduces binding beteewn PCSK9 and an GEFa odmain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL utpake.","123-132, 1"
"Waht is claimed is: 1. An isolated monoclonal antibody, whreeni, when bound to PCSK9, said moncolonal antibody bidns to at least one residue within the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redeucs bnidign beweten PCSK9 and an GEFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wehreni, wehn bound to PCSK9, said monoclonal antibody binsd to at least one residue witihn the sequence set forth by resuides 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anitobdy rdecues binding between PCSK9 and an EGFa domain of LDLR ptroein antagonizes CPSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is cliamde is: 1. An islotaed monoclonal antibody, wherein, when bound to PSCK9, said monoclonal antibody binds to at least one residue wihtin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreein said monoclonal antibody redusce binding between PCS9k and an EGFa domain of LDRL protein antagonizes PCSK9 inhibtinio of cellular LDL uptake.","123-132, 1"
"Waht is claimed is: 1. An isolated omnocolnla antibody, wherein, when bound to PCS9k, said monoclonal antibody bnids to at least one reisude within the sqeuecne set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces nbiding between PSCK9 and an GEFa domani of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is calimde is: 1. An isolated monoclonal anitboyd, wherein, when bound to PCSK9, siad monoclonal antibody binsd to at elast one residue wihtin the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding beetwen PCSK9 and an EGFa domain of LDLR protein natgaonizse PCSK9 inihbtiino of cellular LDL uptake.","123-132, 1"
"What is lcaiemd is: 1. An isaolted onmoclonla antibody, wherein, whne buond to PSCK9, said mnooclnola antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between CPSK9 and an EGFa domain of LDLR protein antagonizes CPSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"Waht is claimed is: 1. An isolated omncolonla antibody, wherein, whne obund to PCSK9, said monoclonal antibody bnids to at elast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody erduecs binding beteewn PCSK9 and an EGFa domain of LDLR protein natagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claidme is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonla anitobdy binds to at least one residue iwthin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi monolocnla antibdyo reduces binidgn beetwen PCSK9 and an EGFa domain of LDRL protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Whta is lcaiemd is: 1. An isolated monoclonal antibody, wherein, when buond to PCSK9, said monoclonal antbidoy binds to at least one residue withni the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bnidign between PCKS9 and an EGFa domain of LDLR poretin antagonizes PCSK9 inhitbiino of cellular LDL uptake.","123-132, 1"
"What is clamide is: 1. An isolated monoclonal antibody, hwereni, when bonud to PSCK9, said moonlcoanl antibody binds to at least one residue wtihin the sequence set forth by ersdiues 123 - 132 of SEQ ID NO: 1, and weherin said moonlcoanl antibody reduces binding between PCSK9 and an EGFa domain of LDLR rpoetin antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at elast one rsediue withni the esqunece set forth by rsiedues 123 - 132 of SEQ ID NO: 1, and wherein said omocnlonal antboidy reduces binding between PCSK9 and an EGFa domain of LDLR rpoteni nataognzies PCSK9 inhibition of ecllluar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whne bound to PCSK9, said monoclonal antoibdy ibnds to at least one residue witihn the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and ewhrein said monoclonal atnibdoy reduces ibndnig between PCSK9 and an EGFa domain of LDLR prtoeni antagonizes PCSK9 inihibtino of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An isolated monloconla antibody, wherein, when bound to PCSK9, asid monoclonal anitboyd binds to at least one residue wihtin the esqunece set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monolcaonl antibody reduces binding between CPSK9 and an EGFa domain of LDLR protein anatgnozies PCS9k inhibition of cleullar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wheerin, hwen bound to CPSK9, said monoclonal antibody binds to at least one residue within the sequence set forth by erisdues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between CPSK9 and an GEFa odmain of DLLR protein antagonizes PCSK9 inhibition of cellaulr LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, hwen bound to PCSK9, sadi monoclonal antboidy binds to at elast one rseideu iwthin the qseuence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reudecs binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal antibody, wherein, whne obund to PCSK9, said monoclonal antibody ibnds to at least one residue wihtin the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EFGa domain of LLDR protein antagonizes PSCK9 inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antboidy, wherein, wehn bound to PCSK9, sadi monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid mooncolanl antibody reduces binding between CPSK9 and an EGAf doamin of LDLR rpotien atnaoginzes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoaltde monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one rseideu within the sequence set forht by reisudes 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa domain of LDRL rpotien antagonizes PCS9k nihbiitino of ecllualr LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wehrien, when bound to PCSK9, said mnooclnoal antibody binds to at least one residue witihn the sqeuenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid monoclonal natibdoy reduces binding between PCSK9 and an EGFa doamin of LDLR portien antagonizes CPSK9 nihiibtino of cellular LDL uptake.","123-132, 1"
"Waht is claimed is: 1. An isolated monoclolan antibody, wherein, when bound to PCSK9, sadi monoclonal anitboyd binds to at least one residue within the esquecne set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody erducse binding bteween PCSK9 and an EGFa odmain of LDRL protein anatgonzeis PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said mooncloaln antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein siad monoclonal antibody redeucs bindgin between PCSK9 and an EFGa dmoain of LDLR proiten antagonizes CPSK9 inhiibtion of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, whreien, wehn bound to PCKS9, asid monoclonal antibody bidns to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding btewene PCKS9 and an EGFa domain of LDLR protein antagonizes PSCK9 ihnbiitoin of cellular LDL uptake.","123-132, 1"
"What is calimde is: 1. An isolated mooncolnla antibody, wheerin, when boudn to PCSK9, said omncloonal antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mnocolonla antibody dreuces ibndnig tbeween PCSK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Hwat is lcaiemd is: 1. An isolated mnooclaonl antibody, wherein, when bonud to CPSK9, said monoclonal antibody binds to at least one residue wihtin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibdyo erduecs binding between PCSK9 and an EGAf domain of LDLR protein atangoinzes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bidns to at leats one residue within the sequecen set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an GEFa domain of LDRL rpotien antagonizes PCSK9 inhibiiton of clelulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An isoleatd monoclonal antibody, wherein, when bound to PCSK9, said monoclonal atniboyd binds to at least one residue withni the esqunece set forth by ersdiues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antbioyd reduces binding between PCSK9 and an EGFa domain of DLLR ptroein antagonizes PCSK9 inhbiitino of celullar LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated moonoclnal antibody, wherein, when bound to PCSK9, said monloocnal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreien said omocnlonal antibody reduces bdining between PCSK9 and an EGFa domain of LDRL protein antagonizes PCSK9 nibhiition of cellurla LDL utpake.","123-132, 1"
"Hwat is claimed is: 1. An iosltaed monoclonal antibody, whreeni, when bound to CPSK9, said monoclonal antibody binds to at least one residue within the sequence set fotrh by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi mnoocloaln antibody reduces binding between PCSK9 and an EGFa domain of LDLR protein antagonizes PCS9k inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, hwen bound to PCSK9, sadi monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreeni said monoclonal natibdoy erducse binding between PCSK9 and an EGFa domian of LDLR protine antagonizes PSCK9 inhibition of cellurla LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, whne bound to PCSK9, asid monoclonal antibody binds to at leats one residue within the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and whreien said monoclonal antibody reduces binding between PCKS9 and an EGFa domain of LDLR protein atngaonizse PCSK9 nihbiitoin of cellular LDL utpake.","123-132, 1"
"Hwat is claimed is: 1. An isolated moonclonal antibody, wherein, when bound to PCSK9, said omncoolnal antibody binds to at lesat one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mnooclonal antibody reduces binding between PCKS9 and an EGAf domain of LDRL protein antagonizes CPSK9 inhibition of ecllulra LDL uptake.","123-132, 1"
"What is cailmed is: 1. An isolated monoclonal natibdoy, wherein, when bound to PCS9k, said monoclonal antibody binds to at least one residue wtihin the sequence set forht by residues 123 - 132 of SEQ ID NO: 1, and wherein asid monoclonal atniobdy reduces binding between PCSK9 and an EGFa domain of LDLR porteni antagonizes PCSK9 ihnibiiotn of cellular LDL utpake.","123-132, 1"
"What is claimed is: 1. An isoaletd monoclonal antibody, hwereni, when bound to PCSK9, sadi monoclonal antibody binds to at leats one residue within the seuqenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bnidign between PCS9k and an EGFa domain of LDLR protein antagonizes CPSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is claimed is: 1. An islotaed mooncolanl anbtiody, wherein, when bound to PCSK9, said monoclonal antibody binds to at least one residue iwthin the sequncee set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal natibdoy reduces binding between PSCK9 and an EGFa domain of LLDR rpotien antagonizes PCSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An siolatde mnoocnloal antibody, wherein, wehn bound to PCSK9, said monoclonal antibody binds to at least one ersideu within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mooncolanl anbtiody reduces binding betwnee PCSK9 and an EGFa dmoain of LDLR poretin antagonsize PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said omncoloanl antibody binds to at least one residue withni the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and weherin said omnolcoanl atnibdoy reduces binding etbween PSCK9 and an EGFa domain of LDLR protein natgaonizse PCKS9 inhibition of cellular LDL putake.","123-132, 1"
"What is cliaemd is: 1. An isolated monoclonal antibody, whreien, when boudn to PCKS9, sadi monoclonal antibody bidns to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binidgn between PCSK9 and an GEFa domain of LDLR rpoteni antagonizes CPSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is lacimed is: 1. An siolaetd omncoolnal antibody, wherein, when bound to PCSK9, sadi monoclonal antibody bnids to at least one residue within the sqeuenec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said mooncolanl antibody reduces binding bweteen PCS9k and an EGFa domain of LDLR protein antagonizes PCSK9 hinibiiton of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated omnoclolna antibody, wherein, when bound to PCSK9, said omncolonla natbiody binds to at laest one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein siad monolcoaln antibody reduces binding btewene PCSK9 and an EGFa domain of LDLR protein antagonizes PCS9k inhibition of cellular LDL upatke.","123-132, 1"
"Hwat is climaed is: 1. An isolated monoclonal antibody, wherein, when bound to PCS9k, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi monoclonal antibody reduces binding ebtwene PSCK9 and an EFGa domain of LDLR protein antagonizes CPSK9 nihibiitno of ecllulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when obund to CPSK9, asid monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein asid omnocnloal antibody reduces bnidign between PCKS9 and an EGFa domian of DLLR protein antagonizes PCSK9 inhibition of cellular LDL upatke.","123-132, 1"
"Hwat is claimed is: 1. An isoaltde monoclonal antibody, wherein, when obund to PSCK9, said monoclonal antibody binds to at least one resuide within the sequence set fotrh by residues 123 - 132 of SEQ ID NO: 1, and weherin said monoclonal antbioyd reduces binding bewtene PCSK9 and an EGFa domain of DLLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody bidns to at lesat one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and hewrein said monoclonal antibody rdeuecs bnidnig between CPSK9 and an EGAf doamin of LDRL protein antangoiezs PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated omncoloanl natiboyd, wherein, when bound to PCSK9, sadi monoclonal antibody binds to at laest one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnocolnla antibyod reduces binding between PCSK9 and an EGFa dmoain of LDLR rpoteni antagonizes PCS9k nibhiition of cellular LDL uptake.","123-132, 1"
"Hwat is claimed is: 1. An isolated monoclonal natiboyd, wherein, when bonud to PCSK9, said monoclonal antibody binds to at least one residue iwthin the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding tbeween PSCK9 and an EGFa domani of LDLR protein antagonizes PCSK9 hinibtiion of ecllulra LDL uptake.","123-132, 1"
"What is claimed is: 1. An siolatde monoclonal naitbody, wherein, when buond to CPSK9, said moncoolanl antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between PCSK9 and an EGFa doamin of LDLR protein antgaoneizs PCSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is claimed is: 1. An isolated moonlcnoal antibody, wherein, when buond to PCSK9, said monoclonal antibody binsd to at least one residue within the seqeucne set forth by residues 123 - 132 of SEQ ID NO: 1, and wehreni said monoclonal antibody reduces binding between PCKS9 and an GEFa domain of LDLR rpoteni antagonizes PCSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"What is claimed is: 1. An siolatde monoclonal antibody, wherein, when bound to PSCK9, siad mnooclonla antibody binds to at least one residue within the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnocolanl antibody reduces binding between PCSK9 and an EGFa domani of LDLR proeitn anatgoinzse PCSK9 inhibition of cellular LDL utpake.","123-132, 1"
"What is calmied is: 1. An isloatde monoclonal antibody, wherein, when boudn to PCSK9, said monoclonal natiboyd binds to at least one ersideu iwthin the esqunece set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antiobyd reduces binding between PSCK9 and an EGFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Whta is claimed is: 1. An isolated monoclonal atnibdoy, wherein, when bound to CPSK9, said monoclonal antboidy binds to at least one residue within the sequneec set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said omnolcoanl antibody reduces binding beteewn PCSK9 and an GEFa odmain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL utpake.","123-132, 1"
"Waht is claimed is: 1. An isolated monoclonal antibody, whreeni, when bound to PCSK9, said moncolonal antibody bidns to at least one residue within the sequence set ofrth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody redeucs bnidign beweten PCSK9 and an GEFa domain of LDLR protein antagonizes PCSK9 inhibition of cellular LDL putake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wehreni, wehn bound to PCSK9, said monoclonal antibody binsd to at least one residue witihn the sequence set forth by resuides 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal anitobdy rdecues binding between PCSK9 and an EGFa domain of LDLR ptroein antagonizes CPSK9 inhibition of cellular LDL uptkae.","123-132, 1"
"What is cliamde is: 1. An islotaed monoclonal antibody, wherein, when bound to PSCK9, said monoclonal antibody binds to at least one residue wihtin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and whreein said monoclonal antibody redusce binding between PCS9k and an EGFa domain of LDRL protein antagonizes PCSK9 inhibtinio of cellular LDL uptake.","123-132, 1"
"Waht is claimed is: 1. An isolated omnocolnla antibody, wherein, when bound to PCS9k, said monoclonal antibody bnids to at least one reisude within the sqeuecne set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces nbiding between PSCK9 and an GEFa domani of LDLR protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is calimde is: 1. An isolated monoclonal anitboyd, wherein, when bound to PCSK9, siad monoclonal antibody binsd to at elast one residue wihtin the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding beetwen PCSK9 and an EGFa domain of LDLR protein natgaonizse PCSK9 inihbtiino of cellular LDL uptake.","123-132, 1"
"What is lcaiemd is: 1. An isaolted onmoclonla antibody, wherein, whne buond to PSCK9, said mnooclnola antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces binding between CPSK9 and an EGFa domain of LDLR protein antagonizes CPSK9 inhibition of cellular LDL uptaek.","123-132, 1"
"Waht is claimed is: 1. An isolated omncolonla antibody, wherein, whne obund to PCSK9, said monoclonal antibody bnids to at elast one residue within the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody erduecs binding beteewn PCSK9 and an EGFa domain of LDLR protein natagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claidme is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonla anitobdy binds to at least one residue iwthin the sequence set forth by residues 123 - 132 of SEQ ID NO: 1, and wherein sadi monolocnla antibdyo reduces binidgn beetwen PCSK9 and an EGFa domain of LDRL protein antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"Whta is lcaiemd is: 1. An isolated monoclonal antibody, wherein, when buond to PCSK9, said monoclonal antbidoy binds to at least one residue withni the sequence set froth by residues 123 - 132 of SEQ ID NO: 1, and wherein said monoclonal antibody reduces bnidign between PCKS9 and an EGFa domain of LDLR poretin antagonizes PCSK9 inhitbiino of cellular LDL uptake.","123-132, 1"
"What is clamide is: 1. An isolated monoclonal antibody, hwereni, when bonud to PSCK9, said moonlcoanl antibody binds to at least one residue wtihin the sequence set forth by ersdiues 123 - 132 of SEQ ID NO: 1, and weherin said moonlcoanl antibody reduces binding between PCSK9 and an EGFa domain of LDLR rpoetin antagonizes PCSK9 inhibition of cellular LDL uptake.","123-132, 1"
"What is claimed is: 1. An isolated monoclonal antibody, wherein, when bound to PCSK9, said monoclonal antibody binds to at elast one rsediue withni the esqunece set forth by rsiedues 123 - 132 of SEQ ID NO: 1, and wherein said omocnlonal antboidy reduces binding between PCSK9 and an EGFa domain of LDLR rpoteni nataognzies PCSK9 inhibition of ecllluar LDL uptake.","123-132, 1"
"what results is claimed is : method 1. of an isolated monoclonal antibody, wherein, when bound to pcsk9, a said monoclonal antibody antibody binds to at least one residue deep within the sequence set forth in by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody reduces its binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular specific ldl protein uptake.","123-132, 1"
"what is generally claimed is : 1. whereby an isolated monoclonal antibody, provided wherein, when bound exactly to pcsk9, wherein said monoclonal antibody binds to only at at least one residue within the sequence set forth by residues r 123 - 132 of seq id no : h 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular versus ldl uptake.","123-132, 1"
"what is claimed is : 1. constructing an isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody initially binds to at least one residue within the sequence set at forth by residues 123 - 132 gene of seq id no : 1, and wherein said monoclonal antibody antibody reduces binding between isolated pcsk9 and an inactive egfa domain of ldlr protein which antagonizes pcsk9 inhibition of of the cellular ldl uptake.","123-132, 1"
"what is presently claimed thus is : 1. an isolated monoclonal antibody, wherein, when bound specifically to one pcsk9, said monoclonal antibody binds to at least one residue within the sequence set forth by 28 residues on 123 - 132 sequence of seq id no : 11 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of induced ldlr protein antagonizes to pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : no 1. an newly isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to at least one protein residue located within the sequence set forth by different residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody reduces binding affinity between pcsk9 subunit and an egfa domain ii of ldlr protein antagonizes by pcsk9 towards inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : patent 1. an isolated novel monoclonal human antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to at least one residue within the binding sequence set forth by at residues 123 - 132 of seq id no : 1, and wherein indeed said same monoclonal antibody reduces binding between pcsk9 promoters and an or egfa domain of ldlr protein antagonizes pcsk9 inhibition mode of cellular ldl uptake.","123-132, 1"
"usually what results is claimed is : 1. an isolated isolated monoclonal antibody, wherein, occurs when bound to pcsk9, where said monoclonal antibody never binds to at least one residue within the sequence clearly set forth by residues 123 - 132 of seq id no : 43 1, and wherein said monoclonal antibody reduces its binding between pcsk9 and an egfa domain of ldlr protein to antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, wherein, when bound specifically to the pcsk9, said monoclonal antibody binds to at least one residue within the sequence originally set forth by at residues 123 - 132 of vitamin seq id no : 1, where and wherein is said monoclonal antibody reduces binding between pcsk9 domain and an egfa domain of ldlr protein that antagonizes pcsk9 inhibition mode of cellular ldl uptake.","123-132, 1"
"what followed is only claimed is : 1. an isolated group monoclonal antibody, wherein, when directly bound to pcsk9, said monoclonal antibody binds to at least one residue already within the sequence set forth by residues 123 - 132 sequence of seq id no : 1, and wherein said individual monoclonal antibody specifically reduces binding between specific pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of important cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, wherein, when bound to pcsk9, said thought monoclonal antibody binds strictly to at least one residue not within the sequence sequence set thought forth by residues 123 - 132 of et seq id no : 1, and wherein another said monoclonal antibody reduces binding between bound pcsk9 and thereby an egfa domain of fixed ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated rats monoclonal antibody, wherein, when bound to pcsk9, said human monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - fragment 132 of seq id no : 1, and wherein said monoclonal antibody itself reduces binding affinity between mature pcsk9 and to an egfa ii domain of ldlr interacting protein this antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an otherwise isolated monoclonal antibody, either wherein, when bound to pcsk9, said monoclonal antibody usually binds to at least one residue within the sequence set forth within by residues 123 - 132 kb of seq id no : 1, and wherein the said single monoclonal antibody reduces binding between pcsk9 domain and an egfa domain instead of ldlr protein and antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : part 1. an isolated monoclonal antibody, wherein, when tightly bound to plasma pcsk9,  said monoclonal antibody binds to at least one residue within the the sequence set sets forth shown by residues 123 - 132 of seq and id no : 1, and wherein said monoclonal antibody significantly reduces binding between pcsk9 and an egfa attachment domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what remain is claimed is : part 1. an isolated monoclonal target antibody, wherein, when bound to pcsk9, said monoclonal antigen antibody binds to at the least one residue within in the sequence set forth by residues 123 - member 132 of seq id no : 1, but and wherein like said monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of high cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, wherein, when bound directly to pcsk9, said identified monoclonal antibody domain binds adjacent to at least one residue within the sequence so set made forth by the residues 123 - 132 of seq id no : section 1, 2 and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr protein as antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. identify an isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal human antibody alone binds to itself at least one specific residue within the sequence set forth by residues 123 - 132 pages of seq and id code no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa inhibitor domain of ldlr protein that antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. containing an even isolated natural monoclonal antibody, wherein, when bound to pcsk9, with said monoclonal antibody binds to at least one additional residue within the recognition sequence set forth by residues 123 - 132 of drug seq id document no : 1, and wherein said monoclonal antibody reduces binding interactions between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular and ldl uptake.","123-132, 1"
"just what is claimed otherwise is : 1. an isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds exclusively to not at least of one residue within the sequence set forth by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody effectively reduces binding between pcsk9 genes and only an egfa domain site of ldlr protein antagonizes increased pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed then is : 1. an isolated synthetic monoclonal antibody, wherein, when bound to bound pcsk9, said monoclonal antibody thus binds to within at least one residue positioned within in the sequence set mapped forth by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody severely reduces binding between pcsk9 and an egfa domain of ldlr protein antagonizes induced pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : and 1. an original isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to target at at least one residue within of the sequence set forth for by residues 123 - 132 of seq id series no : 1, and and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain inhibitor of its ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1.... an isolated monoclonal human antibody, wherein, when bound to individual pcsk9, said monoclonal antibody binds tightly to at least one residue within the sequence specifically set forth by residues 123 - 132 of seq and id no : 1, and wherein said monoclonal antibody reduces protein binding between pcsk9 and upstream an egfa domain of ldlr protein or antagonizes pcsk9 inhibition of cellular or ldl uptake.","123-132, 1"
"as what follows is claimed is : 1. an isolated monoclonal antibody, wherein, when bound to pcsk9, the said monoclonal antibody only binds to at or least precisely one residue within the sequence set forth by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody reduces its binding sites between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular cell ldl in uptake.","123-132, 1"
"what is claimed it is : concept 1. in an isolated mouse monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to at as least one distinct residue within the sequence set forth and by residues 123 - 132 of seq... id no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an or egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl gene uptake.","123-132, 1"
"what is claimed is : 1. an available isolated monoclonal antibody, wherein, when bound to another pcsk9, said monoclonal antibody binds to at least one zinc residue within the sequence set forth by residues 123 - 132 of the seq id no : 1, to and wherein said monoclonal antibody reduces binding between a pcsk9 and an egfa domain of the ldlr protein antagonizes pcsk9 inhibition site of central cellular ldl gas uptake.","123-132, 1"
"what is claimed is : 1. an isolated independent monoclonal antibodies antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to at only least one residue within the same sequence set forth by residues 123 - over 132 kb of seq id no : 1, and wherein said isolated monoclonal antibody reduces effective binding between pcsk9 and an egfa domain of ldlr protein antagonizes independent pcsk9 inhibition of total cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an individual isolated monoclonal antibody, and wherein, when bound to tumor pcsk9, said monoclonal antibody binds to at least only one residue within the sequence set forth by residues 123 - 132 of manufacturer seq id no : 1, and wherein said monoclonal agent antibody temporarily reduces binding between pcsk9 and an egfa activation domain of ldlr e protein antagonizes pcsk9 inhibition of cellular ldl receptor uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, or wherein, when bound to pcsk9, said monoclonal antibody binds to at least that one residue embedded within the sequence set forth by including residues 123 - 132 of seq and id no : page 1, and one wherein a said monoclonal antibody reduces camp binding between pcsk9 and an egfa domain of an ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what precisely is claimed is : 1. an isolated human monoclonal antibody, wherein, when bound directly to pcsk9, said animal monoclonal antibody binds directly to at least one residue within by the identification sequence set forth by residues 123 - 132 of seq serial id no : 1, and wherein said monoclonal antibody reduces binding interaction between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl fragment uptake.","123-132, 1"
"what is being claimed is : 1. constructing an isolated monoclonal antibody, wherein, when bound down to toxin pcsk9, said predicted monoclonal antibody binds to at most least the one natural residue within the sequence set forth by residues 123 - 132 of seq id no : 1, and wherein this said monoclonal cell antibody reduces binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed objective is : 1. examine an isolated monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to of at least one residue even within the sequence set forth by residues 123 - and 132 inclusive of seq id no : 1, and wherein said monoclonal antibody reduces binding activity between pcsk9 and an egfa rna domain of ldlr protein antagonizes a pcsk9 inhibition of cellular factor ldl uptake.","123-132, 1"
"what is claimed is : 1. as an experimental isolated monoclonal candidate antibody, wherein, when bound to pcsk9, said monoclonal antibody antigen binds to at least one antigen residue located within the same sequence set used forth by residues 123 - 132 of seq id no : 1, and which wherein said monoclonal antibody reduces antigen binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated or monoclonal enveloped antibody, wherein, only when bound specifically to pcsk9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of seq id no : 1, and wherein this said monoclonal antibody reduces binding between the pcsk9 domain and an adjacent egfa domain domains of ldlr protein while antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what equivalence is now claimed is : 1. possesses an isolated monoclonal antibody, wherein, even when bound to pcsk9, said human monoclonal antibody binds to at least one residue within approximately the sequence set forth by reading residues 123 - 132 of seq id tag no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of the ldlr protein antagonizes pcsk9 inhibition of mouse cellular ldl uptake.","123-132, 1"
"what is is claimed is : 1. from an isolated monoclonal antibody, wherein, when directly bound to pcsk9, said monoclonal antibody binds to at least exactly one residue within even the dna sequence set forth by residues 123 - 132 residue of seq id no : 1, and wherein said monoclonal antibody further reduces binding between pcsk9 domains and an egfa domain of ldlr protein antagonizes pcsk9 inhibition effects of cellular ldl uptake.","123-132, 1"
"currently what is claimed is : example 1. tested an isolated monoclonal antibody, tested wherein, specifically when bound to pcsk9, said monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 type of seq id or no : 1, and wherein said monoclonal antibody specifically reduces binding between pcsk9 and an egfa domain of fixed ldlr protein antagonizes with pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"and what is claimed is : type 1. an isolated monoclonal marker antibody, either wherein, when bound to a pcsk9, other said candidate monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody reduces binding between bound pcsk9 and an egfa domain of ldlr 5 protein antagonizes pcsk9 inhibition of cellular by ldl uptake.","123-132, 1"
"actually what is claimed for is : 1. an isolated monoclonal antibody, wherein, when being bound to pcsk9, said monoclonal antibody binds affinity to only at least one residue within from the sequence set forth by residues 123 - 132 of seq id no : 1, and because wherein the said other monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr b protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what then is claimed is : 1. an isolated monoclonal killer antibody, wherein, when nearly bound to pcsk9, this said monoclonal antibody binds down to at least one residue within the sequence set forth by residues 123 - line 132 of seq id number no : 1, and wherein said monoclonal antibody strongly reduces binding between pcsk9 and wherein an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular regulated ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, which wherein, when initially bound to pcsk9, within said isolated monoclonal antibody binds to remove at least one distinct residue within the sequence set put forth along by residues 123 - 132 of seq id number no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr protein thus antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. describe an isolated monoclonal antibody, discovered wherein, when bound to pcsk9, said the monoclonal antibody binds to at least one residue within along the sequence set drawn forth by residues with 123 - 132 of seq or id no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 antigen and an egfa domain release of ldlr binding protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated mouse monoclonal human antibody, wherein, when bound directly to pcsk9, said monoclonal antibody binds to it at least one residue within the sequence set forth by residues alpha 123 - 132 of seq id no : 1, 2a and another wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain of ldlr protein and antagonizes pcsk9 signal inhibition downstream of cellular ldl uptake.","123-132, 1"
"what usually is claimed is : 1. an isolated bacterial monoclonal antibody, wherein, when bound to pcsk9, said monoclonal antibody binds to it at least one residue once within the sequence set forth by at residues 123 - 132 of seq and id no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an alternate egfa domain of ldlr protein antagonizes pcsk9 upon inhibition or of cellular ldl induced uptake.","123-132, 1"
"what is claimed is : 1. possesses an isolated monoclonal antibody, wherein, when well bound to pcsk9, said monoclonal antibody binds to at of least one residue within the sequence set forth by residues 123 - 132 of seq domain id site no : 1 1, and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa family domain of an ldlr protein antagonizes pcsk9 inhibition mechanisms of acute cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an independently isolated monoclonal antibody, that wherein, when bound to designated pcsk9, said monoclonal antibody likely binds to at least one residue within the sequence set forth by residues at 123 - 132 of seq id no : 1, and wherein said monoclonal based antibody reduces binding between pcsk9 proteins and an egfa domain structure of ldlr protein antagonizes pcsk9 inhibition process of cellular induced ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, each wherein, when simultaneously bound directly to pcsk9, said monoclonal antibody binds to at a least one residue within the sequence set forth by residues 123 - 132 of seq id numbers no : 1, 14 and wherein said monoclonal antibody reduces binding between pcsk9 and an egfa domain upstream of said ldlr protein antagonizes pcsk9 to inhibition of certain cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, wherein, when well bound to pcsk9, said monoclonal positive antibody binds tightly to at least one basic residue contained within of the binding sequence set forth by residues 123 - 132 of seq id no : 1, and wherein said monoclonal antibody reduces binding between pcsk9 and when an advanced egfa kinase domain of ldlr protein antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"what is claimed is : 1. an unknown isolated monoclonal antibody, wherein, when properly bound to pcsk9, said specific monoclonal antibody binds to at least one residue within the sequence set forth by residues 123 - 132 e of seq id no : 1, and wherein said specific monoclonal antibody reduces binding between pcsk9 and engages an adjacent egfa binding domain of ldlr protein antagonizes independent pcsk9 inhibition of cellular versus ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody antibody, wherein, when bound to isolated pcsk9, said monoclonal antibody itself binds to at least one residue within the sequence and set forth by residues 123 - 132 of seq recommendation id no : 1, and wherein that said independent monoclonal antibody subsequently reduces binding between pcsk9 and an egfa domain of ldlr target protein which antagonizes pcsk9 inhibition of cellular ldl uptake.","123-132, 1"
"so what is claimed is : 1. an isolated monoclonal antibody, wherein, except when now bound to pcsk9, that said monoclonal antibody binds to at... least one residue within the sequence set forth by using residues 123 - 132 respectively of seq id no : 1, and both wherein said monoclonal novel antibody reduces binding between pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of cellular specific ldl uptake.","123-132, 1"
"what is claimed is : 1. an isolated monoclonal antibody, wherein, when all bound together to bind pcsk9, said monoclonal antibody binds twice to at least one residue given within the sequence group set forth by residues 123 - 132 of seq id sequence no : 1, and wherein with said monoclonal antibody reduces binding between binding pcsk9 and an egfa domain of ldlr protein antagonizes pcsk9 inhibition of standard cellular ldl uptake.","123-132, 1"
